SCHEMBL13561970

SCHEMBL13561970

CN1CCCC(N(C)C(=O)OC(C)(C)C)C1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ HSD11B1 P28845 1/20 0.49
▸ KDM4D Q6B0I6 1/20 0.39
▸ RET P07949 1/20 0.38
▸ USP30 Q70CQ3 2/20 0.37
▸ PDE10A Q9Y233 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ SPR P35270 3/20 0.36
▸ JAK2 O60674 1/20 0.36
▸ JAK1 P23458 1/20 0.36
▸ JAK3 P52333 1/20 0.36
▸ AAK1 Q2M2I8 1/20 0.36
▸ KIF18A Q8NI77 1/20 0.35
▸ KAT8 Q9H7Z6 1/20 0.35
▸ MEN1 O00255 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10196708 1.00 HSD11B1 (0.49) HSD11B1KDM4DRETUSP30PDE10A
SCHEMBL10196718 1.00 HSD11B1 (0.49) HSD11B1KDM4DRETUSP30PDE10A
SCHEMBL10106553 0.91 HSD11B1 (0.54) HSD11B1KDM4DUSP30PDE10ASPR
SCHEMBL12021484 0.91 HSD11B1 (0.54) HSD11B1KDM4DUSP30PDE10ASPR
SCHEMBL10106549 0.91 HSD11B1 (0.54) HSD11B1KDM4DUSP30PDE10ASPR
SCHEMBL14820383 0.87 HSD11B1 (0.49) HSD11B1KDM4DUSP30PDE10ASPR
SCHEMBL1009303 0.86 SMN1; SMN2 (0.37) HSD11B1SMN1; SMN2MEN1ALDH1A1MAPT
SCHEMBL16530071 0.85 HSD11B1 (0.50) HSD11B1KDM4DUSP30PDE10ASPR
SCHEMBL18078630 0.84 SMN1; SMN2 (0.35) HSD11B1SMN1; SMN2MEN1ALDH1A1MAPT
SCHEMBL1009304 0.84 SMN1; SMN2 (0.35) HSD11B1SMN1; SMN2MEN1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018136661-A1 SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS ANDREWS STEVEN W (US) 2018-07-26 — — WO disclosed
EP-2518067-B1 DERIVATIVES OF N-[(1H-PYRAZOL-1-YL)ARYL]-1H-INDOLE OR 1H- INDAZOLE-3-CARBOXAMIDE AND THEIR THERAPEUTIC USES AS P2Y12 ANTAGONISTS SANOFI SA (FR) 2014-03-05 — — EP disclosed
US-8623862-B2 Derivatives of N-[(1H-pyrazol-1-yl)aryl]-1H-indole or 1H-indazole-3-carboxamide, preparation thereof and applications thereof in therapeutics SANOFI (FR) 2014-01-07 — — US disclosed
US-8623862-B2 Derivatives of N-[(1H-pyrazol-1-yl)aryl]-1H-indole or 1H-indazole-3-carboxamide, preparation thereof and applications thereof in therapeutics SANOFI (FR) 2014-01-07 — — US disclosed
US-20120277205-A1 DERIVATIVES OF N-[(1H-PYRAZOL-1-YL)ARYL]-1H-INDOLE OR 1H-INDAZOLE-3-CARBOXAMIDE, PREPARATION THEREOF AND APPLICATIONS THEREOF IN THERAPEUTICS SANOFI (FR) 2012-11-01 — — US disclosed
US-20120277205-A1 DERIVATIVES OF N-[(1H-PYRAZOL-1-YL)ARYL]-1H-INDOLE OR 1H-INDAZOLE-3-CARBOXAMIDE, PREPARATION THEREOF AND APPLICATIONS THEREOF IN THERAPEUTICS SANOFI (FR) 2012-11-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120277205-A1 DERIVATIVES OF N-[(1H-PYRAZOL-1-YL)ARYL]-1H-INDOLE OR 1H-INDAZOLE-3-CARBOXAMIDE, PREPARATION THEREOF AND APPLICATIONS THEREOF IN THERAPEUTICS NTRK3, NTRK1, NTRK2 HSD11B1 1372/4885KDM4D 3993/4885RET 184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback